Navigation Links
EuroPCR in Medical News

Volcano Announces OCT Activities at EuroPCR 2009

Volcano's Axsun Laser - At the Heart of OCT SAN DIEGO and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC ), a leader in the development, manufacturing and sales of products for the diagnosis of coronary and peripheral artery disease, today highlights it...

Abbott Announces EuroPCR 2009 Activities

- New data to be presented on Abbott's market-leading XIENCE V(R) stent - Educational information available on XIENCE PRIME(TM), Abbott's next-generation drug eluting stent in development BARCELONA, Spain, May 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) today announced the company...

Boston Scientific Announces Schedule for EuroPCR 2009

NATICK, Mass., May 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's events and news announcements at the annual EuroPCR Scientific Program, which runs from May 19 to 22 in Barcelona, Spain. "We are pleased to be announcing...

CorNova to Present at the Glimpse into the Future: Emerging Drug-Eluting Stents Symposium at EuroPCR 2009

S. Eric Ryan, M.D., Will Discuss the Valecor Platinum(TM) Coronary Stent System on the FiberHalo(TM) Balloon Angioplasty Catheter BURLINGTON, Mass., May 14 /PRNewswire/ -- CorNova Inc. today announced S. Eric Ryan, M.D., the company's chairman and chief executive officer, will present the Val...

LightLab Imaging Introduces World's Highest Resolution OCT System for Intracoronary Imaging at EuroPCR 2009

Launch of C7XR(TM) FD-OCT Imaging System and Companion C7 Dragonfly(TM) Imaging Catheter Strengthen LightLab's Market Leadership WESTFORD, Mass., May 14 /PRNewswire/ -- LightLab Imaging Inc., the pioneer and leader in the development of Optical Coherence Tomography (OCT) for vascular and othe...

PLC Medical Systems to Demonstrate RenalGuard(TM) at EuroPCR 2008

FRANKLIN, Mass., May 12 /PRNewswire-FirstCall/ -- PLC Systems Inc. (AMEX: PLC ), a company focused on innovative cardiac and vascular medical device-based technologies, announced today that it will demonstrate its RenalGuard System(TM) at EuroPCR, the annual meeting of the European Associatio...

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

...y Consistent with Superior Results from Randomized Clinical Trials BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at europcr from an international, post-approval, single-arm study show that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstr...

SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System

... narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual europcr Scientific Program in Barcelona. SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 trea...

XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention

... the publication after presenting it at the annual europcr meeting. "I am very pleased to congratulate Dr. ...ll that need." The paper and presentation at the europcr meeting discussed the previously released positive...s. EuroIntervention is the official publication of europcr and the European Association of Percutaneous Cardi...

TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program

...nd non-diabetic patients. Analysis of the data was presented by David A. Cox, M.D., F.A.C.C., and John M. Lasala, M.D., Ph.D., F.A.C.C., at the annual europcr Scientific Program in Barcelona. "The ARRIVE diabetic subset data demonstrated that the TAXUS Stent mitigated the adverse effect of diabetes as a ri...
EuroPCR in Medical Technology

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented a...

PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009

Live Case Demonstrating RenalGuard To Be Presented FRANKLIN, Mass., May 15 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard Sy...

Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents

Randomized TRIAS HR Pilot Study Compares Genous, Boston Scientific's Taxus(R) Other Presentations Focus on Real-World Use of Genous, Stent's Performance in Patients with AMI, Those Who Could Not Tolerate Dual-Antiplatelet Therapy ...

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting

Company Will Host Webcast to Review Data Tuesday, May 13 at 1:00 p.m. EDT (7:00 p.m. CEST) BARCELONA, Spain and MENLO PARK, Calif., May 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced positive six-month follow-up data from the CUSTOM III clin...

Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008

Other Data Presentations to Focus on Use of Pro-Healing Stent with AMI Patients and Those Who Cannot Tolerate Dual-Antiplatelet Therapy HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both a randomized pilot study and the real-world registry use of OrbusNeich's Genous Bio...

XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week

Webcast to Review CUSTOM III Six-Month Data to be held Tuesday, May 13th MENLO PARK, Calif., May 7 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT ) today announced that six-month follow-up data from the CUSTOM III trial will be presented at EuroPCR, taking place May 13 to 16 in Barcelona...

Boston Scientific Announces Schedule for EuroPcr 2007

Company to release broad range of clinical data on leading drug-eluting stent portfolio NATICK, Mass., May 15, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the schedule of the Company's major events and press announcements at the annual Paris Course on Revasculariza...

XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting

Trial Included One of the Most Challenging Patient Populations Studied of Any Drug-Eluting Stent (DES) Clinical Trial BARCELONA and MENLO PARK, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-month follow-up data from the CUSTOM II clinical trial, which assessed t...

Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principal investigators for the COSTAR II (CObalt Chromium STent with Antiproliferative for Restenosis) trial, the pivotal study for the CoStar(R) cobalt chromium paclitaxel-eluting coronary stent, presented today the clinical trial results of the stu...

Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adve...
EuroPCR in Biological Technology

InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patien...

Prescient Medical, Inc. to Present Data on Identification and Treatment of Rupture-Prone Coronary Plaques at EuroPCR 2008

Company Pursues Strategy of Reducing Heart Attack Deaths by Shielding High-Risk Plaques in Coronary Arteries DOYLESTOWN, Pa., May 8 /PRNewswire/ --- Prescient Medical, Inc., a privately held medical device company dedicated to reducing deaths from heart attacks, will present n...

SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System

...t narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual europcr Scientific Program in Barcelona. SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 treated...

First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter

...s with coronary artery disease." Live patient case to be broadcast at europcr Conference this week On Wednesday, May 20, Dr. van der Ent will be pe...orming a live case with the combined catheter from the Thoraxcenter for the europcr Conference taking place this week in Barcelona, Spain from May 19 - 22, 200...

Boston Scientific Welcomes Launch of Syntax Score Website

...YNTAX Score(TM), a novel angiographic tool used to measure the complexity of coronary artery disease. The Company made the announcement at the annual europcr Scientific Program in Barcelona. The SYNTAX Score was developed in connection with the SYNTAX trial, the first randomized, controlled clinical tr...

Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability

...s. Over and Under(R) PCS was presented by Dr. Haim Danenberg, Head of Interventional Cardiology Unit and the company's medical director, at the annual europcr meeting. Study was performed in phantom and porcine coronaries. Over and Under(R) PCS appeared to be significantly superior in deliverability in both ...

Volcano Announces Placement of 1,000th s5 and s5i IVUS Imaging System

... 2006. This announcement comes just prior to Volcano's participation in the europcr 2008 Congress, to be held in Barcelona, Spain, from May 12-15th. During the...xible than ever before. Presence at EuroPCR08 Volcano's presence at the europcr 2008 Congress in Barcelona will include live case transmissions with IVUS, ...

Biopure Announces 2008 First Quarter Financial Results

... Association of Interventional Cardiology. EIJ is a peer-reviewed journal of interventional cardiovascular medicine and is the official publication of europcr and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). The accepted manuscript reports on the Company's first pilot isch...
Other Tags
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 “After my mom’s ... then had a stroke and loss the use of his left ... to design a way to help people like them enjoy eating ... created a prototype for the PATRICIA CAROL HALL PLATE (P C ... PLATE) offers a more ergonomic way to eat for individuals who ...
(Date:7/12/2014)... York, New York (PRWEB) July 12, 2014 ... continue to move forward in U.S. courts, Bernstein Liebhard ... ties elevated metal ion levels to the failure of ... July 2nd issue of The Journal of Bone & ... had received unilateral Articular Surface Replacement prostheses at least ...
(Date:7/12/2014)... 12, 2014 For those who are unfamiliar ... readily absorb the nutrients in food. The enzymes literally break ... small enough to be absorbed by human bodies. According Dr. ... of enzymes in regular food is the cause of many ... was started by Michelle DelPresto, a mother of 3 who ...
(Date:7/12/2014)... 12, 2014 “Critical Care Therapeutics ... and Late-Stage Four-Factor PCCs and Recombinant Products to ... critical care market in the US, UK, France, ... provides an estimation of market size for 2013, ... critical care indications that are being treated using ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As reported in ... Institute of Standards and Technology), the June 25th, 2014 Supreme ... electronic discovery world. It was also met with ... depending on whether it was seen from an individual privacy ... much is fact, there is now precedent which will require ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5
(Date:7/10/2014)... Florida , July 1, 2014 ... pave way for convenience and improved security: NXT-ID, Inc. (OTCBB: ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a ... pleased to announce that the second series of 30 second ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
Other Contents